Starpharma Holdings (ASX:SPL) - Stock Price, News & Analysis

SPL Stock Overview

A biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide.

About the company

SPL fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings have grown 6.5% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (A$41M)

Starpharma Holdings Limited Competitors

Little Green Pharma

ASX:LGP

AU$37.7m

Vitura Health

ASX:VIT

AU$56.4m

Althea Group Holdings

ASX:AGH

AU$22.3m

Percheron Therapeutics

ASX:PER

AU$70.3m

Price History & Performance

Summary of all time highs, changes and price drops for Starpharma Holdings
Historical stock prices
Current Share Price	AU$0.10
52 Week High	AU$0.20
52 Week Low	AU$0.086
Beta	0.77
11 Month Change	3.09%
3 Month Change	7.53%
1 Year Change	-25.93%
33 Year Change	-90.99%
5 Year Change	-92.48%
Change since IPO	-87.50%

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Dec 18

Recent updates

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Dec 18

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Nov 22

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Mar 21

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Mar 02

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Feb 10

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Jan 20

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

Dec 28

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Dec 07

Shareholder Returns

	SPL	AU Pharmaceuticals	AU Market
7D	9.9%	-2.9%	-0.6%
1Y	-25.9%	58.6%	16.5%

Return vs Industry: SPL underperformed the Australian Pharmaceuticals industry which returned 58.6% over the past year.

Return vs Market: SPL underperformed the Australian Market which returned 16.5% over the past year.

Price Volatility

Is SPL's price volatile compared to industry and market?
SPL volatility
SPL Average Weekly Movement	5.1%
Pharmaceuticals Industry Average Movement	11.7%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.8%
10% least volatile stocks in AU Market	3.6%

Stable Share Price: SPL has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: SPL's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1997	40	Cheryl Maley	starpharma.com

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial.

Starpharma Holdings Limited Fundamentals Summary

How do Starpharma Holdings's earnings and revenue compare to its market cap?
SPL fundamental statistics
Market cap	AU$40.90m
Earnings (TTM)	-AU$8.16m
Revenue (TTM)	AU$9.76m

4.3x

P/S Ratio

-5.1x

P/E Ratio

Is SPL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SPL income statement (TTM)
Revenue	AU$9.76m
Cost of Revenue	AU$10.69m
Gross Profit	-AU$929.00k
Other Expenses	AU$7.24m
Earnings	-AU$8.16m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.02
Gross Margin	-9.52%
Net Profit Margin	-83.69%
Debt/Equity Ratio	2.8%

How did SPL perform over the long term?

See historical performance and comparison

SPL Stock Overview

Rewards

Risk Analysis

Starpharma Holdings Limited Competitors

ASX:LGP

AU$37.7m

ASX:VIT

AU$56.4m

ASX:AGH

AU$22.3m

ASX:PER

AU$70.3m

Price History & Performance

Recent News & Updates

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023)

Non-Executive Director recently bought AU$80k worth of stock

First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023)

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Recent updates

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023)

Non-Executive Director recently bought AU$80k worth of stock

First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023)

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.04 loss in FY 2022)

New minor risk - Share price stability

Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer

New minor risk - Market cap size

First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022)

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023

Starpharma Holdings Limited Announces Resignation of Nigel Baade as Company Secretary

Starpharma Achieves Marketing Authorization of the Nasal Spray Product, VIRALEZETM, in Indonesia

Starpharma Holdings Limited Announces Positive AZD0466 Clinical Data Presented by Astrazeneca

Starpharma Holdings Limited Announces Management Changes

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Starpharma Holdings Limited Launches VIRALEZE in Hong Kong and Macau

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2022

Starpharma Holdings Limited Presents Compelling Data in Prostate Cancer At ESMO

Starpharma Holdings Limited Announces New Clinical Data for Dep Cabazitaxel in Prostate Cancer

Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.05 loss in FY 2021)

Starpharma Announces VIRALEZE Protects Against Omicron in Viral Challenge Model

Starpharma Announces SPL7013, the Antiviral Agent in VIRALEZETM Nasal Spray

Starpharma Holdings Limited Appoints Jeff Davies as Director

Starpharma Holdings Limited Announces Relaunch of VIRALEZETM in UK

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Starpharma Announces SPL7013 in Viraleze Virucidal Against Omicron

Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely

Starpharma Holdings Limited Announces Positive Interim Results from Its Ongoing Phase 2 Trial of DEP® Cabazitaxel

Starpharma Announces US Patent and Trademark Office Has Granted New Patent in Relation to DEP® Cabazitaxel

Independent Non-Executive Director recently bought AU$71k worth of stock

Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.039 loss in FY 2020)

Starpharma Holdings Limited Announces Publication of New Data Demonstrating the Protective Efficacy of VIRALEZETM Antiviral Nasal Spray against SARS-CoV-2 Challenge in Vivo

Independent Non-Executive Deputy Chairman Peter Turvey has left the company

We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth

Starpharma Releases New Data About SPL7013

Forecast to breakeven in 2022

Starpharma Holdings Limited's VIRALEZE Antiviral Nasal Spray Registered for Sale in India

Starpharma Holdings Limited Announces VIRALEZE SPL7013 Highly Active in UK Variant of Coronavirus

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

Starpharma Announces DEP HER2-Lutetium Outperforms in Human Breast Cancer Model

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Starpharma Signs DEP ADC Research Agreement with MSD

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Starpharma Holdings Limited Announces AZD0466 Clinical DEP Program Global Expansion

New 90-day high: AU$1.80

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Price target raised to AU$2.03

New 90-day high: AU$1.68

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?